# FDA recall D-0727-2026

> **Fresenius Kabi USA, LLC** · Class II · drug recall initiated 2026-07-16.

## Product

Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial:  63323-286-05

## Reason for recall

Presence of Particulate Matter: Hair was found in products

## Distribution

Nationwide within in the USA

## Key facts

- **Recall number:** D-0727-2026
- **Recalling firm:** Fresenius Kabi USA, LLC
- **Classification:** Class II
- **Product type:** drug
- **Status:** Ongoing
- **Initiation date:** 2026-07-16
- **Report date:** 2026-07-29

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Lake Zurich, IL, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0727-2026

## Citation

> AI Analytics. FDA recall D-0727-2026. Retrieved 2026-09-01 from https://api.ai-analytics.org/recall/D-0727-2026. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*